Research and Markets (http://www.researchandmarkets.com/research/x4qjj7/recurrent_head) has announced the addition of the "Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

  • Advaxis, Inc.
  • Amgen Inc.
  • AVEO Pharmaceuticals, Inc.
  • Critical Outcome Technologies Inc.
  • Daiichi Sankyo Company, Limited
  • Genentech, Inc.
  • Glycotope GmbH
  • Immunovative Therapies, Ltd.
  • Laboratoires Pierre Fabre SA
  • Mabion SA
  • MedImmune, LLC
  • Merck & Co., Inc.
  • Novartis AG
  • Oncolytics Biotech Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Panacea Biotec Limited
  • PCI Biotech AS
  • Shionogi & Co., Ltd.
  • Symphogen A/S
  • VentiRx Pharmaceuticals, Inc.

For more information visit http://www.researchandmarkets.com/research/x4qjj7/recurrent_head

Research and MarketsLaura Wood, Senior Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: Oncology